Quick Order Cart

Cat. No. ARG34623

ALDH3A2 Knockout HAP1 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone Marrow

  • Disease:

    Chronic myeloid leukemia

The ALDH3A2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the ALDH3A2 gene in near-haploid HAP1 cells. ALDH3A2, regulated by PPAR?? and NRF2, encodes an NAD+-dependent enzyme that oxidizes fatty aldehydes to fatty acids, crucial for aldehyde detoxification and sphingolipid metabolism. Its disruption leads to cytotoxic aldehyde accumulation, mimicking Sj?gren-Larsson syndrome pathology. This polyclonal knockout model is suitable for fatty aldehyde detoxification studies, lipid metabolism research, and disease modeling using assays such as aldehyde dehydrogenase activity tests, LC-MS-based aldehyde quantification, ROS detection, and proliferation assays under aldehyde challenge.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HAP1

    Sex of Donor

    Male

    Age

    40 years

    Derived From Site

    Bone marrow

    Gene Name

    ALDH3A2

    Gene Identifier

    NCBI Gene ID 224

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    IMDM

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ALDH3A2 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ALDH3A2 gene in HAP1 cells. This product provides a heterogeneous pool of cells with targeted ALDH3A2 gene disruption, serving as a loss-of-function model for functional studies.

HAP1 is a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells, exhibiting male origin, adherent growth, and fibroblast-like morphology. Its haploid nature simplifies gene editing and phenotypic analysis, making it a preferred system for genetic screening and functional genomics.

ALDH3A2 encodes a NAD+-dependent aldehyde dehydrogenase that oxidizes long-chain aliphatic aldehydes to fatty acids, critical for fatty aldehyde detoxification and sphingolipid metabolism. The enzyme operates as a homodimer and is transcriptionally activated by PPAR?? and NRF2, key regulators of lipid and oxidative stress responses. Its catalytic activity drives downstream pathways including fatty acid accumulation and mitigation of aldehyde-induced cytotoxicity. Knockout of ALDH3A2 disrupts these processes, leading to accumulation of cytotoxic fatty aldehydes and aberrant sphingolipid profiles.

In HAP1 cells, ALDH3A2 disruption recapitulates molecular hallmarks of Sj?gren-Larsson syndrome, an autosomal recessive disorder featuring ichthyosis and spastic paraplegia. The accumulation of fatty aldehydes induces oxidative stress and impairs cellular proliferation under aldehyde challenge, providing a physiologically relevant model. The haploid background enhances genotype-phenotype correlation, facilitating studies on peroxisomal lipid metabolism and the interplay between PPAR??/NRF2 signaling and sphingolipid homeostasis.

Research applications encompass fatty aldehyde detoxification, Sj?gren-Larsson syndrome modeling, and lipid metabolism investigations. Typical assays include aldehyde dehydrogenase activity measurements with hexadecanal substrate, fatty aldehyde quantification via LC-MS, ROS detection, and sphingolipid profiling. Proliferation assays under aldehyde stress and immunofluorescence further characterize the knockout phenotype. This polyclonal population is suitable for high-content screening and mechanistic dissection. For inquiries, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)